» Articles » PMID: 22234969

High-mobility Group Box 1 Activates Caspase-1 and Promotes Hepatocellular Carcinoma Invasiveness and Metastases

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2012 Jan 12
PMID 22234969
Citations 131
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Hypoxia is often found in solid tumors and is associated with tumor progression and poor clinical outcomes. The exact mechanisms related to hypoxia-induced invasion and metastasis remain unclear. We elucidated the mechanism by which the nuclear-damage-associated molecular pattern molecule, high-mobility group box 1 (HMGB1), released under hypoxic stress, can induce an inflammatory response to promote invasion and metastasis in hepatocellular carcinoma (HCC) cells. Caspase-1 activation was found to occur in hypoxic HCC cells in a process that was dependent on the extracellular release of HMGB1 and subsequent activation of both Toll-like receptor 4 (TLR4)- and receptor for advanced glycation endproducts (RAGE)-signaling pathways. Downstream from hypoxia-induced caspase-1 activation, cleavage and release of proinflammatory cytokines interleukin (IL)-1β and -18 occurred. We further demonstrate that overexpression of HMGB1 or treatment with recombinant HMGB1 enhanced the invasiveness of HCC cells, whereas stable knockdown of HMGB1 remarkably reduced HCC invasion. Moreover, in a murine model of HCC pulmonary metastasis, stable knockdown of HMGB1 suppressed HCC invasion and metastasis.

Conclusion: These results suggest that in hypoxic HCC cells, HMGB1 activates TLR4- and RAGE-signaling pathways to induce caspase-1 activation with the subsequent production of multiple inflammatory mediators, which, in turn, promote cancer invasion and metastasis.

Citing Articles

High Mobility Group Box 1 (HMGB1): Molecular Signaling and Potential Therapeutic Strategies.

Datta S, Rahman M, Koka S, Boini K Cells. 2024; 13(23).

PMID: 39682695 PMC: 11639863. DOI: 10.3390/cells13231946.


Emerging Roles of High-mobility Group Box-1 in Liver Disease.

Wang L, Dong Z, Zhang Y, Peng L J Clin Transl Hepatol. 2024; 12(12):1043-1056.

PMID: 39649031 PMC: 11622203. DOI: 10.14218/JCTH.2024.00317.


A pan-cancer analysis of the oncogenic function of HMGB1 in human tumors.

Yang H, Zhao X, Li X, Wang X, Pu Y, Wei D Biochem Biophys Rep. 2024; 40:101851.

PMID: 39582753 PMC: 11584604. DOI: 10.1016/j.bbrep.2024.101851.


Programmed cell death in hepatocellular carcinoma: mechanisms and therapeutic prospects.

Wu X, Cao J, Wan X, Du S Cell Death Discov. 2024; 10(1):356.

PMID: 39117626 PMC: 11310460. DOI: 10.1038/s41420-024-02116-x.


The significant mechanism and treatments of cell death in heatstroke.

Wang Z, Zhu J, Zhang D, Lv J, Wu L, Liu Z Apoptosis. 2024; 29(7-8):967-980.

PMID: 38886312 DOI: 10.1007/s10495-024-01979-w.


References
1.
Rampone B, Schiavone B, Confuorto G . Current management of hepatocellular cancer. Curr Oncol Rep. 2010; 12(3):186-92. DOI: 10.1007/s11912-010-0094-3. View

2.
Carrascal M, Mendoza L, Valcarcel M, Salado C, Egilegor E, Telleria N . Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res. 2003; 63(2):491-7. View

3.
Di Bisceglie A, Simpson L, Lotze M, Hoofnagle J . Development of hepatocellular carcinoma among patients with chronic liver disease due to hepatitis C viral infection. J Clin Gastroenterol. 1994; 19(3):222-6. DOI: 10.1097/00004836-199410000-00011. View

4.
Gong H, Zuliani P, Komuravelli A, Faeder J, Clarke E . Analysis and verification of the HMGB1 signaling pathway. BMC Bioinformatics. 2010; 11 Suppl 7:S10. PMC: 2957678. DOI: 10.1186/1471-2105-11-S7-S10. View

5.
Davis B, Wen H, Ting J . The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol. 2011; 29:707-35. PMC: 4067317. DOI: 10.1146/annurev-immunol-031210-101405. View